title: An integrated approach to the treatment of chiasmatic-hypothalamic gliomas.
abstract: The treatment of visual pathway gliomas is controversial. The many retrospective studies reporting outcome data for patients with chiasmatic/hypothalamic gliomas are difficult to interpret for several reasons. First the natural history of these tumors is erratic with some reports suggesting that most visual pathway gliomas are hamartomas and follow an indolent course, and others reporting 10-year survival rates of close to 60%. Second, earlier studies did not clearly indicate which patients had neurofibromatosis type 1 (NF1) and recent evidence suggests that the natural history of optic gliomas is more favorable in patients with NF1. Third the methods and accuracy of diagnosis have changed dramatically and patients diagnosed before and after the advent of CT/MR imaging have often been included in the same series. While surgical resection is usually not a viable option for definitive treatment of these tumors, recent studies have shown favorable results after subtotal resection in selected patients. The efficacy of radiotherapy has not been unequivocally demonstrated and treatment-related morbidity has become a major concern, in particular, adverse effects on cognition and growth. Chemotherapy has been advanced as an viable alternative to avoid or delay the adverse affects of RT, but the long-term outcome benefits and adverse effects of treatment are just being defined. Despite the limitations of currently available information, sufficient data are now available to rational management quotelines for the majority of children with chiasmatic/hypothalamic gliomas.
authors.affiliation: Department of Neurology, Children's National Medical Center, Washington, DC, USA.
authors.forename: M
authors.initials: M
authors.lastname: Garvey
authors.forename: R J
authors.initials: RJ
authors.lastname: Packer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D003390:Cranial Nerve Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D018450:Disease Progression; D005910:Glioma / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D009897:Optic Chiasm; D011878:Radiotherapy; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents